Business Wire

Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) ...
Nasdaq

Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy

Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference ID# 8879216 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic ...

Catalent and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing

Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments ...
Seeking Alpha

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its ...
GEN - Genetic Engineering and Biotechnology News

ASGCT 2026: Rare Instance of AAV Integration into Human Genome Linked to Brain Tumor

The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
Business Insider

Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional ...
Labroots

Considerations in the Use of Analytical Ultracentrifugation for Characterization of AAV Gene Delivery Vectors

Analytical Ultracentrifugation (AUC) in the biopharmaceutical industry has traditionally been employed in the analysis of aggregation and higher order structure in protein drug products. More recently ...
Nasdaq

Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership

NEW YORK and BASEL, Switzerland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, ...
Business Insider

Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders

License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) ...

VectorBuilder to Present on Advancing AAV-Based Therapies at ARVO 2026

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in ...
Seeking Alpha

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from ...